Real-World Coverage With Influenza, Pneumococcal, and Herpes Zoster Vaccines Among Patients With Rheumatic Diseases in a Nationwide Healthcare Plan
Authors' conclusion
This study demonstrated suboptimal coverage of influenza, pneumococcal, and HZ vaccination in patients with RA, PsA, and SLE, in particular among younger adults in Israel.
Study context
- Population
- Adults with rheumatoid arthritis (RA), psoriatic arthritis (PsA) or systemic lupus erythematosus (SLE) in a nationwide healthcare plan (Maccabi), Israel, as of April 30, 2019
- Participants
- 14,528 adults
- Exposure
- Vaccination coverage across RA, PsA and SLE
- RAn = 6,932
- PsAn = 4,395
- SLEn = 1,951
- > 1 conditionn = 1,250
- Outcome
- Age-specific vaccination coverage for influenza (past year), pneumococcal (PPSV23 and/or PCV13) and live-attenuated HZ vaccines (past 5 years)
Methodological detailsretrospective, Maccabi Healthcare Services database, logistic regression
- Retrospective
- Maccabi Healthcare Services database
- Logistic regression
Main finding
As reported in the abstract
Influenza vaccine coverage (past year)
Observational data: associations, not effects.
Further findings
| Outcome | RA | PsA | SLE |
|---|---|---|---|
| PPSV23 coverage | 19.6% | 16.2% | 12.6% |
Coverage in elderly (≥ 65 years)
- Influenza vaccine in the past year
- 63.2%
- PPSV23 in the past 5 years or at age ≥ 65
- 83.4%
PCV13 and herpes zoster (HZ) coverage, overall study population
- PCV13
- 4.8%
- HZ
- 3.6%
Predictors of vaccination
- Central residence and treatment with corticosteroids and b/tsDMARDs within the past 5 years: significant predictors across all vaccines
- P < 0.05
- Other predictors varied by vaccine: female sex (influenza, PPSV23, PCV13), age (influenza, PPSV23), chronic comorbidities (influenza, PPSV23, PCV13), shorter disease duration (PCV13), high socioeconomic status (PCV13, HZ)
Original publication
Real-World Coverage With Influenza, Pneumococcal, and Herpes Zoster Vaccines Among Patients With Rheumatic Diseases in a Nationwide Healthcare Plan. J Rheumatol. Published 1 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →